Ambrisentan Adjunct for IgA Nephropathy Proteinuria: ETA Mechanism, Real-World Evidence, Safety Monitoring

　　1.Why ETA Blockade in IgA

　　Persistent proteinuria and recurrent hematuria mark disease activity in IgA nephropathy and accelerate sclerosis and renal decline.Endothelin-1 via ETA promotes afferent/efferent tone,podocyte injury,mesangial proliferation,inflammation,and interstitial fibrosis;sustained ETA activation raises intraglomerular pressure and protein leakage.Selective ETA antagonism with ambrisentan reduces hemodynamic stress and podocyte barrier damage,so it is investigated as an add-on to reduce proteinuria.It is not disease-modifying for IgA production and does not replace RAAS inhibitors,SGLT2 inhibitors,targeted-release budesonide,steroids,or immunosuppression.

　　2.Adjunctive Use Cases

　　Consider mainly when proteinuria remains above goal after standard care:

　　biopsy-proven primary IgA nephropathy with persistent 24h proteinuria or UPCR above individual target;

　　ACEI/ARB at maximally tolerated dose,with or without SGLT2 inhibitor,still not at goal;

　　progression features such as hypertension,hematuria,falling eGFR,where additional intraglomerular-pressure reduction is reasonable;

　　residual proteinuria after or instead of steroids/immunosuppression,judged by nephrology.

　　Avoid self-use in severe hepatic impairment,significant anemia,uncontrolled volume overload,pregnancy or planning pregnancy,severe hypotension,or unstable recent heart failure/acute kidney injury.Add-only decisions use baseline eGFR,liver tests,hemoglobin,blood pressure,and drug interactions.

　　3.Real-World Evidence

　　Two retrospective/single-center datasets support further study rather than a fixed standard:

　　Peking University First Hospital,147 IgA patients,weeks 4/8/12:baseline 24h protein around 1.16g/d,significant reductions at all visits(P<0.001),eGFR stable over 12 weeks,only 2 discontinuations for edema or liver abnormality.

　　Single-center 169 high-risk IgA patients on ambrisentan≥6 months with propensity-matched historical controls:median UPCR fell 58.4%at 6 months,75.7%achieved≥30%reduction;hematuria measures also improved;greater proteinuria lowering when added to ACEI/ARB or finerenone,but hemoglobin declined.

　　These data suggest ETA add-on lowers proteinuria,yet retrospective design,single site,and historical controls cannot prove long-term renal survival;prospective randomized outcomes by MEST-C subtype,eGFR slope,and safety are still needed.

　　4.Dosing and Monitoring

　　Real-world regimens often use once-daily oral dosing;some protocols start 5mg and titrate individually by tolerance and proteinuria response—never self-escalate.With RAAS or SGLT2,watch blood pressure,volume,and creatinine.At baseline and follow-up:

　　proteinuria:24h protein or UPCR plus urinary RBC sediment;initial review at 4–8 weeks,then every 1–3 months by response;

　　renal function:serum creatinine and eGFR at baseline and after each dose change;watch acute kidney injury;

　　liver:ALT,AST,total/direct bilirubin—ETA agents carry transaminase signals;discontinue or hold if marked abnormality;

　　hematology:hemoglobin/hematocrit—ambrisentan can lower hemoglobin;recheck with fatigue,palpitations,pallor;

　　volume and pressure:weight,ankle edema,seated/standing BP;detect peripheral edema,fluid retention,hypotension;

　　pregnancy:embryofetal risk;exclude pregnancy before use and use contraception in women of childbearing potential;avoid in pregnancy/lactation.

　　5.Safety and Stop Signals

　　Common:peripheral edema,nasal congestion,headache,flushing,hypotension,hemoglobin decline.Seek care for:

　　liver injury:jaundice,dark urine,persistent nausea,marked ALT/AST or bilirubin rise;

　　fluid retention/heart failure:rapid weight gain,marked edema,dyspnea,orthopnea;

　　acute kidney injury:rapid creatinine rise,especially with diuretics,NSAIDs,RAAS/SGLT2 uptitration,or dehydration;

　　severe anemia:falling Hb with angina or dizziness;

　　allergy,chest pain,syncope,or other serious events.

　　A nephrologist decides hold,dose reduction,diuretics,hepatology input,or switch—patients should not increase the dose on their own.